Search clinical trials for: Trametinib Dimethyl Sulfoxide

Total 1206 results

National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Human Genome Research Institute (NHGRI)

Completed

Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease

BRAF V600E Mutation

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

Erdheim-Chester Disease

United States
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI); American Lebanese Syrian Associated Charities...

Recruiting

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Low Grade Glioma (LGG) of Brain With BRAF Aberration | High Grade Glioma (HGG) of the Brain With BRAF Aberration | Low Grade Glioma of Brain With Neurofibromatosis Type 1

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Locally Advanced Melanoma | Unresectable Melanoma | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
Assaf-Harofeh Medical Center

Unknown

Comparative Study Between Hyperbaric Therapy and Intravesical Dimethyl Sulfoxide Instillation for Interstitial Cystitis

Interstitial Cystitis

Israel
Assaf-Harofeh Medical Center

Unknown

DMSO Efficacy in IC/PBS Patients During and After Treatment

Cystitis, Interstitial

Israel
Tishreen University

Completed

Acceleration of Orthodontic Tooth Movement

Mild to Moderate Anterior Mandibular Segment Crowdind

Syrian Arab Republic
U.S. Army Medical Research and Development Command

Completed

Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets

Thrombocytopenia

United States
GlaxoSmithKline

Completed

A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies

Cancer

United States
Nova Scotia Health Authority

Terminated

Trial Comparing Intravesical Cocktail With Intravesical Dimethyl Sulfoxide (DMSO) in Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC)

Interstitial Cystitis | Bladder Diseases

Canada
Mayo Clinic

Completed

Botulin-A Toxin Instillations and Overactive Bladder

Overactive Bladder | Detrusor Instability | Detrusor Hyperreflexia

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Recruiting

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Glioblastoma | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Astrocytoma, Not Otherwise Specified | Anaplastic Ganglioglioma | Anaplastic Pleomorphic Xanthoastrocytoma | WHO Grade 3 Glioma

United States, Puerto Rico
Rabin Medical Center

Unknown

DMSO for Prevention of Capsular Contraction in Alloplastic Breast Reconstruction

Breast Capsular Contracture | Dimethyl Sulfoxide

Israel
NorthShore University HealthSystem

Completed

Bladder Capacity as Objective Measure of Intravesical Treatment of Newly Diagnosed IC

Interstitial Cystitis | Painful Bladder Syndrome
Dennis Bregner Zetner

Completed

Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer (MELADERM)

Breast Cancer | Radiation Dermatitis | Radiation Dermatitis Acute

Denmark
Melanoma Institute Australia
Novartis

Recruiting

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel)

Melanoma

Australia
National Cancer Institute (NCI)
GlaxoSmithKline; Novartis Pharmaceuticals

Active, not recruiting

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...

United States
Memorial Sloan Kettering Cancer Center

Completed

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | KRAS Gene Mutation

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma

United States
GlaxoSmithKline

Completed

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation

Cancer

United States
Medicines Development for Global Health
Imperial College London; Phillip T. and Susan M. Ragon Foundation

Terminated

A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People

HIV Infections

United Kingdom
Maria Sklodowska-Curie National Research Institute...

Completed

Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation. (DMSOconc3)

Multiple Myeloma | Lymphomas | Leukemias

Poland
GlaxoSmithKline

Completed

A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers

Cancer

Japan
Napolitano Mariasanta
Regione Sicilia

Terminated

Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia (MICE)

Thrombocytopenia | Primary Thrombocytopenia,Unspecified | Thrombocytopenia Chemotherapy Induced

Italy
Cairo University
University of Turku

Completed

Clinical Evaluation of Dimethyl Sulfoxide Dentin Pre-treatment

Dental Diseases

Egypt
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Metastatic Melanoma | Recurrent Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Stanford University
Boston Children's Hospital

Recruiting

Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation

Arterial Disease | Venous Malformation

United States
Shanghai Henlius Biotech

Recruiting

HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors

Solid Tumor

China
University Health Network, Toronto

Recruiting

Pilot Study on Trametinib for Surgical Unruptured AVMs (OZUHN-017)

Arteriovenous Malformations

Canada
The Netherlands Cancer Institute
GlaxoSmithKline

Unknown

Lapatinib Plus Trametinib in KRAS Mutant NSCLC (M14LTK)

Colorectal Cancer

Netherlands
Adil Daud
National Comprehensive Cancer Network

Completed

Trametinib With GSK2141795 in BRAF Wild-type Melanoma

Melanoma

United States
Mallinckrodt

Terminated

Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function

Renal Impairment

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor

Gastric Cancer | Metaplasia | Stage I Gastric Cancer | Initial-onset Gastric Cancer

Japan
Jonsson Comprehensive Cancer Center
Novartis

No longer available

Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

Progressive Metastatic Castrate Resistant Prostate Cancer
Asan Medical Center

Unknown

Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation

Cancer | Lung Cancer Metastatic | BRAF V600E

Korea, Republic of
Dana-Farber Cancer Institute
Novartis; National Comprehensive Cancer Network

Terminated

GSK1120212+GSK2141795 for Cervical Cancer

Cervical Cancer

United States
Universitair Ziekenhuis Brussel

Completed

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

Malignant Melanoma

Belgium
Leiden University Medical Center
Novartis

Recruiting

NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) (NEO-ATACT)

Anaplastic Thyroid Cancer

Netherlands
GlaxoSmithKline

Withdrawn

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors

Solid Tumours
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline

Completed

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma | BRAF Mutant Melanoma

United States
Genfit

Recruiting

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma

Cholangiocarcinoma

United States, Puerto Rico
Novartis Pharmaceuticals

Completed

Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

Malignant Melanoma

Portugal
GlaxoSmithKline

Completed

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Solid Tumours

Japan
Novartis Pharmaceuticals

Recruiting

Dabrafenib and/or Trametinib Rollover Study

Melanoma | Solid Tumor | High Grade Glioma | Non Small Cell Lung Cancer | Rare Cancers

Spain, Germany, United States, Argentina, Austria, Denmark, France, Hungary, Netherlands, China, Japan, Thailand

Search clinical trials for: Trametinib Dimethyl Sulfoxide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations